

QUALYST TRANSPORTER SOLUTIONS, LLC AND HEPREGEN CORPORATION LAUNCH HEPATOPAC® B-CLEAR® TRANSPORTER PRODUCT

*HepatoPac® B-CLEAR® Co-Labeled Proprietary Product for Human Liver Transporter Analysis
Provides Pharmaceutical and Chemical Industry with Best-In-Class Performance*

Baltimore, MD, April 20, 2015 – Qualyst Transporter Solutions, LLC (Qualyst) and Hepregen Corporation announced today, at the *American Association of Pharmaceutical Scientists/International Transporter Consortium* (“AAPC/ITC”) Joint Workshop on Drug Transporters, the launch of their first co-developed and co-labeled transporter kit for *in vitro* analysis of chemical transporter proteins in the human liver. The launch of this first application-directed HepatoPac® B-CLEAR® assay kit, provides a product to investigators that can be routinely used for predictive and mechanistic hepatic transporter analysis. This first co-launched kit contains human hepatocytes (liver cells) in Hepregen’s proprietary micro-patterned, co-culture microtiter tissue culture plates and Qualyst’s proprietary transporter culture media. The co-cultures are optimized for transporter analysis using Qualyst’s proprietary hepatobiliary methodology. Moreover, as a part of this launch effort, both companies are continuing their commitment to providing unequalled customer support. Hepregen scientists bring years of experience evaluating metabolite and toxicology data developed using the HepatoPac® platform, and Qualyst scientists provide a wealth of experience interpreting results of measuring concentrations of new chemical entities and their metabolites inside hepatocytes, bile canaliculi and cell culture medium.

“The rapid development of our co-labeled product is the result of an exceptional collaborative effort,” said Christopher Black, Qualyst’s chief executive officer. “Now we can offer Qualyst’s patented and proven B-CLEAR® technology to our customers via a best-in-class HepatoPac® B-CLEAR® transporter kit or as a service provided at our dedicated North Carolina laboratory using this high performance product.”

“This partnership with Qualyst is an example of Hepregen’s commitment to working with premier companies in the industry to provide real solutions to scientists developing new drugs and chemical entities,” commented Dr. Vincent Zurawski, Hepregen’s president and chief executive, adding, “the unique capabilities of the HepatoPac® platform and the proprietary capabilities of the Qualyst B-CLEAR® system have been combined to yield an unmatched level of performance in this first co-developed kit.”

About Qualyst Transporter Solutions, LLC

Qualyst Transporter Solutions commercializes novel and proprietary drug transport and hepatobiliary disposition products for research in drug induced liver injury, hepatotoxicity, drug interactions and drug metabolism. Qualyst Transporter Solutions products and contract services provide clinically-relevant answers to liver-related questions through the use of a proprietary technology, B-CLEAR®, that yields physiologic intracellular concentrations by ensuring proper metabolism and transport function. In addition, Qualyst Transporter Solutions has pioneered an industry-accepted standard of hepatocyte function for cryopreserved human hepatocytes called Transporter Certified™, which is available from most hepatocyte providers.

About Hepregen Corporation

Hepregen Corporation is a leader in innovating unique and proprietary bioengineered micro-liver platforms for use in environmental testing, preventive care, and product development in the pharmaceutical and biopharmaceutical, diagnostic, cosmetics, and chemical industries. The company's micro-liver HepatoPac[®] and HepatoMune[™] cell-based assays are intended to drive a paradigm shift in drug development. The utilities of Hepregen's human, rat, monkey, dog, and multi-species/multi-donor HepatoPac[®] and HepatoMune[™] application-directed products have been validated in collaboration with investigators at several well-known pharmaceutical companies. Additionally, new applications for these products are being tested by Hepregen, its pharmaceutical company customers, and its academic and business partners. Hepregen was founded and initially capitalized by Battelle Ventures and Innovation Valley Partners with technology licensed from the Massachusetts Institute of Technology. The technology was developed by Professor Sangeeta Bhatia, who is a world renowned expert and leader in liver bioengineering for life science and therapeutic applications.

Cautionary Statement Regarding Forward-Looking Statements

This press release may contain forward-looking statements. Such forward-looking statements reflect Hepregen's and Qualyst's expectations about future operating results, performance and opportunities that involve substantial risk and uncertainties. These statements include but are not limited to statements regarding the performance and results of the companies HepatoPac[®] B-CLEAR[®] kits in development. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target," "intend" and "expect" and similar expressions, as they relate to Hepregen Corporation, Qualyst Transporter Solutions or the management of either company are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to Hepregen and Qualyst, and are subject to a number of risks, uncertainties and other factors that could cause the Companies' actual results, performance, prospects and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

Contacts

Qualyst Transporter Solutions LLC
Christopher Black, Chief Executive Officer
Tel: 1-919-313-6500
marketing@qualyst.com

Hepregen Corporation
Katherine Sydney Cook
Tel: 1-781-391-0205
Email: ksydneycook@hepregen.com
www.hepregen.com